Physician profile
Benjamin Diamond
NPI 1992199822
$65,546.04
in general payments reported to CMS, 2019-2025
10 companies · $25K in 2025
The $25K reported for 2025 was more than what 94% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,501 · 2022: $3,583 · 2023: $25K · 2024: $11K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $58K · Travel and Lodging: $1,240 · Food and Beverage: $1,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $58,122.50 |
| Travel and Lodging | $1,240.20 |
| Food and Beverage | $1,098.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Research & Development, LLC | $51,365.00 | 2023-2025 | Darzalex, Tecvayli |
| Janssen Biotech, INC. | $8,479.65 | 2023-2025 | Darzalex, Tecvayli |
| Genzyme Corporation | $4,934.62 | 2021-2024 | |
| Adaptive Biotechnologies Corporation | $187.36 | 2022 | |
| Karyopharm Therapeutics INC. | $181.42 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $120.97 | 2023 | |
| Pfizer INC. | $120.86 | 2023 | |
| Regeneron Pharmaceuticals, INC. | $71.35 | 2022 | |
| Janssen Scientific Affairs, LLC | $42.62 | 2025 | Carvykti, Darzalex, Imbruvica |
| Legend Biotech USA INC. | $42.19 | 2025 | Carvykti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Diamond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.